Trial Profile
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of the Safety and Immunogenicity of AdCOVID Administered as One or Two Doses
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Coronavirus vaccine-Altimmune (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Altimmune
- 09 Aug 2023 Status changed from active, no longer recruiting to completed.
- 14 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 29 Jun 2021 According to an Altimmune media release, based on these data, and in view of the highly competitive COVID-19 vaccine landscape, Altimmune is discontinuing further development of AdCOVID beyond the completion of this Phase 1 trial